Epidemiological and clinical profile, and survival of patients followed for breast cancer between 2010 and 2015 at the Yaounde General Hospital, Cameroon

Stéphane Zingue, Etienne Okobalem Abenguena, Laure Leka Zingue, Alain Brice Tueche, Dieudonné Njamen, Alexandre Benjamin Nkoum, Paul Ndom

Corresponding author: Stéphane Zingue, Department of Medical and Biomedical Engineering, Higher Technical Teachers’ Training College, University of Yaounde I, P.O. Box 886 Ebolowa, Cameroon. stephanezingue@gmail.com

Received: 07 Nov 2020 - Accepted: 17 Jun 2021 - Published: 07 Jul 2021

Keywords: Breast cancer, epidemiological profile, clinical profile, overall survival, Yaoundé General Hospital

Copyright: Stéphane Zingue et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Stéphane Zingue et al. Epidemiological and clinical profile, and survival of patients followed for breast cancer between 2010 and 2015 at the Yaounde General Hospital, Cameroon. Pan African Medical Journal. 2021;39(182). 10.11604/pamj.2021.39.182.26866

Available online at: https://www.panafrican-med-journal.com/content/article/39/182/full

Epidemiological and clinical profile, and survival of patients followed for breast cancer between 2010 and 2015 at the Yaounde General Hospital, Cameroon

Stéphane Zingue1,2,3,8, Etienne Okobalem Abenguena2,3,4, Laure Leka Zingue2, Alain Brice Tueche5, Dieudonné Njamen5, Alexandre Benjamin Nkoum3, Paul Ndom2,4

1Department of Medical and Biomedical Engineering, Higher Technical Teachers’ Training College, University of Yaounde I, P.O. Box 886 Ebolowa, Cameroon, 2Oncology Division, Yaoundé General Hospital, Yaoundé, Cameroon, 3School of Health Sciences, Catholic University of Central Africa, Yaoundé, Cameroon, 4Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I,
Yaoundé, Cameroon, 5Department of Animal Biology and Physiology, Faculty of Science, University of Yaounde I, P.O. Box 812 Yaounde, Cameroon

*Corresponding author
Stéphane Zingue, Department of Medical and Biomedical Engineering, Higher Technical Teachers’ Training College, University of Yaounde I, P.O. Box 886 Ebolowa, Cameroon

Abstract

Introduction: approximately 6000 Cameroonian women died of cancer in 2018, and the breast is the most affected with 2625 new cases. The aim of this study was to establish a pattern of malignant breast tumours in Yaoundé (Cameroon). Methods: this study was a descriptive and analytical retrospective study of breast cancer between January 2010 and December 2015 in Yaoundé General Hospital (YGH) after the Institutional ethics committee approval. The variables studied were the socio-demographic characteristics, risk factors for breast cancer, types of tumours and type of treatments. The 5-year survival was analyzed by the Kaplan-Meier method. The adjusted hazard ratios and their 95% confidence intervals were calculated to assess the association between studied variables and patient survival through the cox regression using SPSS 23 software. The difference was considered significant at p < 0.05. Results: among the 344 files collected in this study, breast cancer patients were predominantly female (96.64%, n = 288) aged 45.39 ± 13.35 years, with invasive ductal carcinoma (68.03%, n = 270), located in the left breast (52%, n= 147). The average tumour size was ~6.5 ± 0.3 cm and diagnosed in grade II of Scarf Bloom Richardson (SBR) in 60% (n= 150) of cases. The 5-year survival was 43.3%. Factors associated with this poor survival were the religion (aHR 5.05, 95% CI: 1.57 - 16.25; p = 0.007 for animist and aHR 4.2, 95% CI: 1.53 - 11.46; p = 0.005 for protestant), location of the tumour (aHR 6.24, 95% CI: 1.58 - 24.60; p = 0.012), tumor height (aHR 0.21, 95% CI: 0.04 - 1.11; p = 0.011) and the time spent before medical treatment (aHR 5.12, 95% CI: 0.39 - 8.38; p = 0.011). Conclusion: the young age, large tumour size and high histological grade in our studied population suggest a weak awareness of women about breast cancer. Action should be taken in early screening to improve the management of breast cancer in Cameroon.

Introduction

The aging of populations is a real demographic revolution. Since the middle of the eighteenth century, the progress made by humanity in the fields of medicine, housing and nutrition has contributed to the improvement of the quality of life of the populations and, consequently, to the aging of the population [1]. However, the increase of the life span of women is followed by many health problems, called diseases of aging. Some authors have shown that these changes in the lifestyle associated with urbanization and the concomitant loss of traditional protective factors in our African societies are positively correlated with the increased incidence of cancer [2].

Cancer can be defined as a heterogeneous group of neoplastic disorders characterized by an anarchic proliferation of monoclonal cells having acquired a transformed phenotype. It is the second largest cause of death worldwide, accounting for more than 9.6 million deaths per year (13% of all deaths worldwide). Breast cancer is the most frequently diagnosed cancer and the leading cause of death from cancer in women worldwide (626, 679 deaths per year) [2, 3]. The overall survival at 5 and 10 years for the breast cancer in Cameroon is estimated to be 30% and 13.2% respectively and is much lower than that of patients in some developed countries, which is between 90% and 82% respectively at 5 and 10 years [4].

Numerous studies have shown that early diagnosis of cancer allows effective management at a lower cost and improve the overall survival of patients with breast cancer [5, 6]. In Cameroon, due to
economic constraints, cultural reasons, the absence of systematic screening policies and also the lack of means of exploration, the management of breast cancer is difficult [7]. This explains why the overall survival at 5 years in Cameroon was found around 30% between January 1992 and December 2010 [4]. In addition, death registration is often incomplete and the recorded cause of death may be inaccurate or missing in this country [8]. Since the scientific data are helpful to take good decisions to ensure improved and equitable cancer care, the present study was undertaken to identify the factors that characterize the overall survival at 5 years in patients with breast cancer at the YGH between January 2010 and December 2015.

Methods

Type of study: this study was a retrospective review of the digital medical records of breast cancer patients followed up at the YGH between January 2010 and December 2015. The study protocols were approved by the Catholic University of Central Africa Institutional Ethical Committee, Cameroon. Patient consent was not required in this retrospective study.

Presentation of YGH: the YGH is one of the most specialized hospitals in the treatment of cancer in Cameroon. It has a number of services specialized in the treatment of cancers such as Radiotherapy, Medical Oncology, Anatomic Pathology, Nuclear medicine, Gynecology and Surgery. Breast cancer patients followed up at the YGH were most often referred from other health facilities and came from all parts of the country.

Sampling: all patients diagnosed with a breast cancer and registered at the YGH during the study period (2010-2015) were considered. A total of 344 medical records were included in this study after a successive and consecutive recruitment of all patient medical records found in the different services. The medical records excluded were those of patients diagnosed with a benign breast tumour, or those whose medical records were not found or incomplete, as well as patients who were not followed up after the diagnosis of their breast cancer.

Study design: all patient medical records obtained in the 5 years study period were reviewed. Collected and analysed data included: the socio-demographic characteristics (age, level of education, reproductive and menopausal status), clinical manifestations (type of tumour, histologic type, histologic grade, type of treatment, severity, lethality, curability). The survival delay of patients within 5 years from the date of unequivocal diagnosis of cancer was obtained by active and passive methods. The passive assessment method of survival was based on medical records. Survival was calculated as the time between the date of diagnosis of cancer and the date of death from any cause or the date of loss to follow up or the date of last follow-up. The active measure consisted to contact the patient or their relatives by phone when the death information were lacking in their medical records. The overall survival at 5 years was calculated by the Kaplan Meier method using SPSS 23 software. Once the data collection was completed, we verified the completeness and likelihood of the information obtained on the collection sheets. We then created an input mask with Epi Info 7 software.

Data analysis: once our data matrix was obtained, it was transferred in "Statistical Package for Social Sciences" (SPSS 23) software for statistical analysis. We report descriptive categorical data with percentage and analysis with Fisher’s exact test, descriptive numerical data with mean and standard deviation, and cox regression univariate analysis was performed. P-values less than 0.1 were considered statistically significant to include the retained variable along with their relative modality in the Cox regression multivariate analysis. Survival was calculated by the Kaplan-Meier method. The adjusted hazard ratios were calculated with their 95% confidence interval, in order to assess the influence between the different variables and survival at 5 years.
Results

Survival at 5 years: among the 344 files collected in this study, 110 cases (68.2%) had died. The overall survival estimated by the Kaplan Meier method is shown in Figure 1. It can be observed that 285 patients (82.3%) survive more than 1 year, 182 (52.93%) survive more than 3 years and only 149 (43.3%) survive 5 years after the diagnosis of their cancer.

General and clinical patient characteristics: the results depicted in Table 1 show that 211 (73%) patients lived in urban areas, while the majority (59 cases, 76%) of patients who succumbed to their cancer before 5 years were in the rural areas. The religions most represented are respectively Catholics (148 cases, 52%) and Protestants (70 cases, 25%). Patients are mostly married (170 cases, 59%). There were 73 (34%) patients in the large "Centre" group and 80 (37%) patients in the "West" group. Ten (3%) patients enrolled in breast cancer during the study period were males. The majority of patients did not have paid employment, we recorded 115 (39%) housewives and 34 (12%) are unemployed. Table 1 also summarizes the bivariate analysis between the general and clinical characteristics and the overall survival at 5 years. Ten (10) variables were analyzed and only the religion was significantly (p = 0.02) associated with the survival at 5 years. The patients belonging to the Islamic and animist religion will be 2.59 times (95% CI: 1.34 - 5.02; p = 0.005) and 2.42 times (95% CI: 1.12 - 5.23; p = 0.024), respectively more likely to die before the 5 years as compared to the catholic.

Risk factor of cancer and histopathological features: the Table 1 also shows that the average age of patients was 45.39 ± 13.35 years, with a range of 13.58 and 84.39 years. The majority (72; 51%) of patients had their first pregnancy between 20 and 24 years. It was found that 96 (38%) patients were already in menopause. It can also be observed in Table 2 that approximately 153 (59%) patients have between 2 and 5 children, while 57 (22%) have minus 2 children. The majority of patients (124 cases, 85%) practiced exclusive breastfeeding and the majority of patients were breastfed less than 4 years throughout their lifetime while only 5 (3%) had a cumulative duration of breastfeeding greater than 16 years.

The Table 2 also shows that the left breast was the most affected (147 cases, 51%), while only 20 patients (7%) have cancer on both breasts. It was observed that in 35 cases (35%) the contro-lateral breast is affected. Moreover, the average tumour size was big (6.5 ± 0.27 cm) and painful in 128 cases (45%). The majority (270 cases, 79%) of tumors was invasive ductal carcinoma, followed by the lobular carcinoma type (15 cases; 5%). The majority of tumours are detected in SBR Grade II (150 cases, 60%) and SBR Grade III (66, 26%). The majority of patients had no associated cancer (291, 98%) and no pathology (137, 80%). However, the most commonly encountered pathologies were high blood pressure in 21 (13%) patients and HIV in 10 (6%) patients. It further appears from Table 2 that following the bivariate analysis only tree variables (location of the tumour, tumour height and SBR grade) out of the eleven analyzed are significantly associated with the overall survival at 5 years. In fact, patients with big tumour (≥ 10 cm) were 1.34 times (95% CI: 0.30 - 6.02; p = 0.021) more likely to die before 5 years than those with a tumour < 5 cm. Moreover, patients with both affected breasts were 1.4 times (95% CI: 0.75 - 2.75; p = 0.091) more likely to die before 5 years than those with one breast affected. Furthermore, patients with a histological SBR grade III were 2.05 times (95% CI: 0.92 - 4.57; p = 0.078) more likely to die before 5 years than those with the SBR grade I.

Management of the cancer: Table 3 depicts the details of the management of patients with breast cancer at YGH from 2010 to 2015. It was found that 234 (79%) patients discovered their tumour by auto palpation, although in 61 (21%) cases the discovery of the tumour was fortuitous. In 200 (68%) cases, the basis of the diagnosis was a biopsy. The majority (105, 26%) of patients have to consult 3 months after the onset of the disease,
however, 80 waited more than one year to be consulted. Otherwise, 147 (52%) patients began the treatment 3 months after the diagnosis of their cancer, while 67 (24%) wait one year to begin their treatment. Chemotherapy was the most administered type of treatment observed in 111 (39%) cases followed closely by the combination of chemotherapy with surgery (93 cases, 33%). Table 4 also shows that out of the five studied variables, two were significantly associated with survival at 5 years. They are the circumstance of the tumour's discovery and the delay before treatment. Indeed, patients who discovered their tumours fortuitously have 1.64 times (95% CI: 1.01 - 2.61; p = 0.037) more risk of dying before 5 years. Patients who had waited more than 12 months to start treatment after the cancer was diagnosed had 6.37 times (95% CI: 3.74 - 7.13; p = 0.001) risk of dying before 5 years as compared to patients who started treatment < 1 month.

**Final model of cox regression multivariate analysis:** six variables were selected in the final model of our study: religion, location of the tumor, tumor height, SBR grade, tumor discovery and delay before treatment. Significant association with the overall survival at 5 years was found with the religion (aHR 5.05, 95% CI: 1.57 - 16.25; p = 0.007 for animist and aHR 4.2, 95% CI: 1.53 - 11.46; p = 0.005 for protestant), location of the tumour (aHR 6.24, 95% CI: 1.58 - 24.60; p = 0.012), tumor height (aHR 0.21, 95% CI: 0.04 - 1.11; p = 0.011) and the time spent before medical treatment (aHR 5.12, 95% CI: 0.39 - 8.38; p = 0.011).

**Discussion**

According to estimation of the World Health Organization, Africa will have 21.7 million new cases of cancer and 13 million deaths in 2030 due to the increase in life expectancy everywhere the world if nothing is done [6]. Cameroon, like other developing countries, is faced with insufficient resources to ensure adequate care for cancer patients, whose magnitude is increasing steadily. In addition, cancer is a public health problem that should be considered in the light of the great morbidity it inflicts on the sick.

The results obtained in this work show that 211 (73%) patients live in urban areas, but the greatest number of patients succumbing to their cancer before 5 years are living in rural environment. Women living in urban zone have a high standard of living and therefore have a breast cancer risk twice as high as those living in rural areas, which is consistent with observations of Ndamba Engbang et al. [8]. As suggested by these authors, women living in urban areas may be more prone to breast cancer because of the stress that prevails in large metropolises. But, we can also incriminate dietary habits and life style, which are different in urban and rural zones. Although the incidence of breast cancer is greater in urban zone than in rural areas, rural women have a weaker survival at 5 years. The multiple therapeutic itineraries of these patients, who generally refer to traditional healers, could be in cause.

The religions most represented are respectively Catholics and Protestants. Patients were mostly married and belonging to Centre and West groups. These observations are in line with those of Cameroon Demographic and Health Survey [9], and could be explained by the fact that Yaoundé is predominantly populated by the Betis (Centre) and the Bamileke (West), and these ethnic groups are strongly represented in Cameroon. Ten patients were men, affording a sex ratio (M/F) of 0.03. These values are similar to those reported by Ndamba Engbang et al. [8], who found a sex ratio (M/F) of 0.02 over the whole population of Cameroon and those of Diallo [10] who found male breast cancers in Bamako in the range of 1-3%. The majority of women patients (178 out of 315) were aged ~45.4 years with a minimum of 13.6 years and a maximum of 84.4 years. This average is higher than that recorded by Essiben et al. [11] in Yaoundé, but lower to that of Ndamba Engbang et al. [8] who found 46 ± 15.9 years. This confirms the increasing occurrence of breast cancer in Africa and especially in Cameroon, where we found in our study that 94 (30%)
patients had breast cancer between 30 and 40 years these 5 years. It was observed that the majority of neoplasms were located on the left breast (51%) cases and that only 7% had both breasts affected. These are in agreement with several reports showing that the left breast most affected that the right one [8, 12].

Just like Ndamba Engbang et al. [8] have found 74% of infiltrating ductal carcinoma in Yaoundé, we found 82% infiltrating ductal carcinoma. The majority of cancers were detected in grade II and grade III. This are divergent with the report of Ly et al. [13], who found that the SBR grade III was the most common among women in sub-Saharan Africa. In Bangui, grade II was the most prominent with 58%, while grades I and II were in the same proportions (21%) [14], which is in agreement with our observations. At the Gynecological Obstetrics and Pediatric Hospital in Yaoundé, Essiben et al. [11] cumulatively regained grades II and III in 89% of their workforce; while Ndamba Engbang et al. [8] found values similar to us (65%) for grade II.

Five-year survival was estimated to be 43.3% in our study, which corroborates with WHO's findings that nearly 60% of patients die within the year of diagnosis in developing countries [15]. Patients with both affected breasts were 1.4 times more likely to die before 5 years than those with one breast affected (p = 0.091). This could be explained by the burden of disease imposed by the two tumors. It was noticed that patients who discovered their cancer incidentally have 1.64 folds more risk of dying before 5 years (p = 0.037) than those who have detected their cancer by practicing auto palpation. In addition, patients who started their treatment ≥ 12 months after the diagnosis of cancer had 6.37 (p = 0.001) fold risk of dying in the next 5 years than those who started their treatment earlier. These are consistent with many reports that the high mortality rates due to breast cancer in sub-Saharan Africa, including Cameroon is due to delayed diagnosis [4]. Indeed, many patients are diagnosed with breast cancer at SBR grades that are often very advanced (Grade II and III), where their vital prognosis is already committed.

The tortuous therapeutic itineraries, and especially the lack of financial resources, can be the cause of this delay of diagnosis and treatment. Indeed, as described by Ndongo et al. [16] patients with breast cancer most often use traditional healers, alternative therapies such as prayer groups, exorcism and Chinese medicine. However, chemotherapy was the most common type of conventional therapy and the most prescribed chemotherapy line in the HGY oncology department was the Adriblastine-Endoxan combination found in 69 (37%) cases (data not shown). The access to chemotherapy in Cameroon is very difficult and patient support his treatment charges, causing both individual and household poverty by curbing the patient’s economic output due to prolonged treatment and adverse effects of treatment [15]. According to a survey carried out in Yaoundé in January-February 2015, 80% of the antimitotics registered in the National List of Medicines Essential are unavailable or expenses (~ from XAF 226,780 to 500,000). Since the monthly average expenditure of care for a patient suffering of breast cancer was estimated at ~ XAF 74, 769, and the fact that the majority of patients are housewives (39.25%), students (8.53%) or widows (3.07%), it becomes comprehensible that the survival at 5 years in Cameroon is very weak.

The main limitation of this study is the large proportion of loss to follow up, which resulted in numerous unrecovered medical records. This difficulty in archiving medical records is very common in our hospitals and is a major issue for research in developing countries. However, the results presented in this study give an idea of the overall survival at 5-year of breast cancer patients in Cameroon and the main factors that influence it.

**Conclusion**

The patients followed at the HGY for breast cancer from 2010 to 2015 have different socio-
The invasive ductal carcinoma was found the predominant type of breast cancer and chemotherapy associated or not to surgery was the most prescribed treatment. The delays in the treatment after diagnosis remain the factor which greatly influences the overall survival at 5 years in Cameroon. Unfortunately, the time between the diagnostic and the start of treatment was found very long because of financial constraints. The young age, large tumour size and high histological grade in our studied population suggest a weak awareness of women about breast cancer. Action should be taken in early screening to improve the management of breast cancer Cameroon.

What is known about this topic

- It is well known that early diagnosis of the breast cancer allows effective management at a lower cost and improve the overall survival of patients;
- In Cameroon, due to economic constraints, the management of breast cancer is difficult;
- Cameroonian authors reported that the overall survival at 5 years in Cameroon was around 30% between January 1992 and December 2010 [4].

What this study adds

- This study brings fresh data on the pattern of breast cancer patient in Cameroon and revealed that: they aged 45.39 ± 13.35 years, with invasive ductal carcinoma (68%), located in the left breast (52%);
- The average tumour size was found ~6.5 ± 0.3 cm and diagnosed in grade II of Scarff Bloom Richardson-SBR in 60% of cases;
- The survival at 5 years in Cameroon from 2010 to 2015 was 43.3%, testifying that efforts are undertaken to fight cancer in Cameroon.

Competing interests

The authors declare no competing interests.

Authors' contributions

Conception and study design: SZ, EOA and ABN. Data collection: SZ, EOA, LLZ, and ABT. Data analysis and interpretation: SZ, EOA, LLZ, ABT and DN. Manuscript drafting: SZ and EOA. Manuscript revision: SZ, EOA, PN and ABN. Guarantor of the study: SZ. All authors read and approved the final version of the manuscript.

Acknowledgments

The authors are greatly thankful to all the patients and/or the parents for their participation in this study.

Tables and figure

Table 1: bivariate analysis between characteristics of patients and survival at 5 years
Table 2: bivariate analysis between histopathological features and survival at 5 years
Table 3: bivariate analysis between management of breast cancer and survival at 5 years
Table 4: cox regression multivariate analysis of factors associated with poor survival
Figure 1: survival curve at 5 years

References

1. Belmin J, Amalberti F, Beguin AM. Infirmier (e) et les soins aux personnes âgées. Edition Masson. 2005;18.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6): 394-424. PubMed | Google Scholar
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1): 7-34. PubMed | Google Scholar
4. Ngowa JDK, Kasia JM, Yomi J, Nana NA, Ngassam A, Domkam I et al. Breast Cancer Survival in Cameroon: Analysis of a Cohort of 404 Patients at the Yaoundé General Hospital. Advances in Breast Cancer Res. 2015;04(02): 44-52. Google Scholar

5. C7e congrès Euro-Africain de Cancérologie (CEAC). Le cancer de la femme et de l’enfant. Accessed 4th May 2020.

6. Adeloye D, Sowunmi OY, Jacobs W, David RA, Adeosun AA, Amuta AO et al. Estimating the incidence of breast cancer in Africa: a systematic review and meta-analysis. J Glob Health. 2018;8(1): 1-21. PubMed|Google Scholar

7. Ngatali CFS, Bolenga Liboko AF, Ndounga E, Mabila Y, Moukassa D, Nkoua-Mbon JB et al. Breast Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Pointe Noire (Congo Brazzaville). Accessed 4th May 2020.

8. Ndamba Engbang JP, Essome H, Mve Koh V, Simo G, Sime Essam JD, Mouelle AS et al. Cancer du sein au Cameroun, profil histopathologique à propos de 3044 cas. Pan Afr Med J. 2015;21: 242. PubMed|Google Scholar

9. Enquête Démographique et de Santé au Cameroun (EDS). Institut National de la Statistique. Ministère de la planification, de la programmation du Développement et de l’aménagement du territoire. 2011; Yaoundé, Cameroun. ORC Macro. Calverlon, Maryland USA.

10. Diallo S. Etude épidémiologique, clinique et histopathologique de cancer de sein diagnostiqué dans les hôpitaux de Bamako et de Kati. Thèse médicinale, Université de Bamako. 2007;73-94.

11. Essiben F, Foumane P, Mboudou ET, Dohbit JS, Mve Koh V, Ndom P. Diagnostic et traitement du cancer de sein au Cameroun: à propos de 65 cas. Mali Med. 2013;28(1): 1-5. PubMed|Google Scholar

12. Lansac J, Lecomte P, Marret H. Gynécologie pour le praticien. Edition Elsevier-Masson 2012; Paris, France.

13. Ly M, Antoine M, André F, Callard P, Bernaudin JF, Diallo DA. Le cancer du sein chez la femme de l’Afrique sub-saharienne: état actuel des connaissances. Bull Cancer. 2011;98(7): 797-806. Google Scholar

14. Koffi B, Sepou A, Doui D, Goumba C, Djabanga S. Aspects épidémiologiques et caractéristiques histologiques des cancers du sein à Bangui. Médecine Afr Noire. 2004;51(2): 112-1. Google Scholar

15. Organisation Mondiale de la Santé (OMS). Profils des pays pour le cancer. Genève, suisse 2014.

16. Ndongo JS, Ntsama Essomba CM, Ongolo-Zogo P. Un Observatoire pour améliorer l’accès aux médicaments contre les maladies chroniques non transmissibles au Cameroun. Centre pour le Développement des Bonnes Pratiques en Santé -Hôpital Central. Yaoundé, Cameroun 2014.
Table 1: bivariate analysis between characteristics of patients and survival at 5 years

| Variables                | Total | Survivor | Deceased | p-value |
|--------------------------|-------|----------|----------|---------|
| **Age (year)**           |       |          |          |         |
| < 30                     | 27    | 11 (41)  | 16 (59)  | 0.930   |
| 30 to 40                 | 86    | 36 (42)  | 50 (58)  |         |
| 40 to 50                 | 78    | 35 (45)  | 43 (55)  |         |
| 50 to 60                 | 70    | 32 (46)  | 38 (54)  |         |
| > 60                     | 32    | 9 (29)   | 23 (71)  |         |
| **Area of residence**    |       |          |          | 0.866   |
| Urban                    | 211   | 101 (48) | 110 (52) |         |
| Rural                    | 78    | 19 (24)  | 59 (76)  |         |
| **Religion**             |       |          |          | 0.022   |
| Catholic                 | 148   | 64 (43)  | 84 (57)  |         |
| Protestant               | 70    | 32 (46)  | 38 (54)  |         |
| Islamic                  | 29    | 10 (35)  | 19 (65)  |         |
| Animist                  | 37    | 17 (46)  | 20 (54)  |         |
| **Marital status**       |       |          |          | 0.459   |
| Single                   | 84    | 35 (42)  | 49 (58)  |         |
| Married                  | 170   | 75 (44)  | 95 (56)  |         |
| Widow                    | 32    | 12 (38)  | 20 (62)  |         |
| **Region of origin**     |       |          |          | 0.312   |
| Centre                   | 73    | 34 (47)  | 39 (53)  |         |
| West                     | 80    | 34 (43)  | 46 (57)  |         |
| North                    | 23    | 10 (44)  | 13 (56)  |         |
| South                    | 34    | 16 (47)  | 18 (53)  |         |
| Foreign                  | 5     | 1 (20)   | 4 (80)   |         |
| **Sex**                  |       |          |          | 0.295   |
| Male                     | 10    | 5 (50)   | 5 (50)   |         |
| Female                   | 288   | 121 (42)| 167 (58) |         |
| **Occupation**           |       |          |          | 0.394   |
| Civil servant            | 65    | 35 (54)  | 30 (46)  |         |
| Private sector           | 61    | 22 (36)  | 39 (64)  |         |
| Retirer                  | 13    | 4 (31)   | 9 (69)   |         |
| Household                | 115   | 41 (36)  | 74 (64)  |         |
| Unemployed               | 39    | 22 (56)  | 17 (44)  |         |
| **Menarche age (year)**  |       |          |          | 0.646   |
| < 13                     | 23    | 10 (44)  | 13 (56)  |         |
| 14 to 16                 | 63    | 25 (40)  | 38 (60)  |         |
| > 17                     | 13    | 4 (31)   | 9 (69)   |         |
| **Age of 1st pregnancy**|       |          |          | 0.180   |
| < 20 years               | 33    | 14 (42)  | 19 (58)  |         |
| 20 to 24 years           | 72    | 23 (32)  | 49 (68)  |         |
| 25 to 29 years           | 20    | 6 (30)   | 14 (70)  |         |
| ≥ 30 years               | 16    | 8 (50)   | 8 (50)   |         |
| **Menopause**            |       |          |          | 0.270   |
| Yes                      | 96    | 44 (46)  | 52 (54)  |         |
| No                       | 165   | 65 (39)  | 100 (61) |         |
### Table 2: bivariate analysis between histopathological features and survival at 5 years

| Variables                          | Total  | Survivor | Deceased | p-value |
|------------------------------------|--------|----------|----------|---------|
| **Location of the tumor**          |        |          |          |         |
| Left breast                        | 147    | 60 (41)  | 87 (59)  | 0.075   |
| Right breast                       | 123    | 52 (42)  | 71 (58)  |         |
| Both                               | 20     | 11 (55)  | 9 (45)   |         |
| **Tumor height**                   |        |          |          |         |
| < 5 cm                             | 111    | 50 (45)  | 61 (55)  | 0.021   |
| 6 to 10 cm                         | 70     | 25 (36)  | 45 (64)  |         |
| > 10 cm                            | 32     | 10 (31)  | 22 (69)  |         |
| **Breast pain**                    |        |          |          |         |
| No                                 | 157    | 65 (41)  | 92 (59)  | 0.164   |
| Yes                                | 128    | 54 (42)  | 74 (58)  |         |
| **Nipple discharge**               |        |          |          |         |
| No                                 | 259    | 101 (39) | 158 (61)| 0.159   |
| Yes                                | 20     | 12 (60)  | 8 (40)   |         |
| **2nd breast affected**            |        |          |          |         |
| No                                 | 262    | 105 (40) | 157 (60)| 0.215   |
| Yes                                | 35     | 21 (60)  | 14 (40)  |         |
| **Type of carcinoma**              |        |          |          |         |
| Invasive ductal                    | 270    | 113 (42) | 157 (58)| 0.345   |
| Invasive lobula                    | 15     | 7 (46)   | 8 (53)   |         |
| Other                              | 9      | 4 (44)   | 5 (55)   |         |
| **SBR grade**                      |        |          |          | 0.066   |
| Grade I                            | 34     | 15 (44)  | 19 (56)  |         |
| Grade II                           | 150    | 69 (46)  | 81 (54)  |         |
| Grade III                          | 66     | 26 (39)  | 40 (61)  |         |
| **Cancer associated**              |        |          |          | 0.896   |
| None                               | 291    | 121 (42) | 170 (58)|         |
| Uterine                            | 3      | 2 (67)   | 1 (33)   |         |
| Ovaries                            | 2      | 2 (100)  | 0        |         |
| **Associated pathology**           |        |          |          | 0.467   |
| HIV                                | 10     | 4 (40)   | 6 (60)   |         |
| HBP                                | 21     | 9 (42)   | 12 (57)  |         |
| Other                              | 14     | 7 (50)   | 7 (50)   |         |
| None                               | 137    | 63 (46)  | 74 (54)  |         |
| **Number of children**             |        |          |          | 0.172   |
| ≤ 1                                | 57     | 25 (44)  | 32 (56)  |         |
| 2 to 5                             | 153    | 96 (63)  | 57 (37)  |         |
| 6 to 10                            | 50     | 24 (48)  | 26 (52)  |         |
| **Cumul breastfeeding**            |        |          |          | 0.412   |
| < 50 months                        | 72     | 28 (39)  | 44 (61)  |         |
| 51 to 100 months                   | 47     | 16 (34)  | 31 (66)  |         |
| 101 to 150 months                  | 30     | 7 (23)   | 23 (77)  |         |
| 151 to 200 months                  | 11     | 5 (45)   | 6 (54)   |         |
| > 200 months                       | 5      | 2 (40)   | 3 (60)   |         |

HR = hazard ration, CI = Confidence interval; the % are in the brackets.
### Table 3: Bivariate analysis between management of breast cancer and survival at 5 years

| Variables                        | Total  | Survivor | Deceased | p-value |
|----------------------------------|--------|----------|----------|---------|
| **Tumor discovery**              |        |          |          | 0.037   |
| Screening                        | 234    | 94 (40)  | 140 (60) |         |
| Fortuitous                       | 61     | 29 (48)  | 32 (52)  |         |
| **Diagnostic base**              |        |          |          | 0.807   |
| Biopsy                           | 200    | 92 (46)  | 108 (54) |         |
| Needle aspiration                | 93     | 32 (35)  | 61 (65)  |         |
| Clinic                           | 3      | 0        | 3 (100)  |         |
| **Diagnostic delay**             |        |          |          | 0.213   |
| < 1 month                        | 29     | 10 (34)  | 19 (65)  |         |
| 1 to 3 months                    | 76     | 33 (43)  | 43 (57)  |         |
| 3 to 6 months                    | 47     | 19 (40)  | 28 (60)  |         |
| 6 to 9 months                    | 32     | 13 (41)  | 19 (59)  |         |
| 9 to 12 months                   | 25     | 9 (36)   | 16 (64)  |         |
| > 12 months                      | 80     | 38 (49)  | 41 (51)  |         |
| **Delay before treatment**       |        |          |          | 0.015   |
| < 1 month                        | 80     | 15 (19)  | 65 (81)  |         |
| 1 to 3 months                    | 67     | 22 (33)  | 45 (67)  |         |
| 3 to 6 months                    | 33     | 12 (36)  | 21 (64)  |         |
| 6 to 9 months                    | 18     | 5 (28)   | 13 (72)  |         |
| 9 to 12 months                   | 12     | 9 (67)   | 3 (33)   |         |
| > 12 months                      | 55     | 53 (96)  | 2 (4)    |         |
| **Type of treatment**            |        |          |          | 0.272   |
| Chemotherapy                     | 111    | 32 (29)  | 79 (71)  |         |
| Surgery                          | 8      | 2 (25)   | 6 (75)   |         |
| Hormonotherapy                   | 2      | 1 (50)   | 1 (50)   |         |
| Chemotherapy + Surgery           | 93     | 40 (43)  | 53 (57)  |         |
| Radiotherapy + Chemothe          | 15     | 11 (73)  | 4 (27)   |         |
| Chemo + Surgery + Radio          | 32     | 14 (44)  | 18 (56)  |         |
| Chemo + Surgery + Horm           | 25     | 24 (96)  | 1 (04)   |         |

HR = hazard ratio, CI = Confidence interval; the % are in the brackets.
### Table 4: cox regression multivariate analysis of factors associated with poor survival

| Variables                          | Univariable analysis | Multivariable analysis |
|------------------------------------|----------------------|------------------------|
|                                    | HR [95% CI]          | p-value                | aHR [95% CI]          | p-value   |
| Religion                           |                      |                        |                        |           |
| Catholic                           | 1                    |                        | 1                      |           |
| Protestant                         | 1.16 [0.69 1.98]     | 0.570                  | 4.2 [1.53 11.46]       | 0.005     |
| Islamic                            | 2.59 [1.34 5.02]     | 0.005                  | 2.68 [0.75 9.52]       | 0.129     |
| Animist                            | 2.42 [1.12 5.23]     | 0.024                  | 5.05 [1.57 16.25]      | 0.007     |
| Location of the tumor              |                      |                        |                        |           |
|                                    |                      |                        |                        |           |
|                                    |                      |                        |                        |           |
|                                    | 0.075                | 0.012                  |                        |           |
| Left breast                        | 1                    |                        | 1                      |           |
| Right breast                       | 0.67 [0.42 1.11]     | 0.290                  | 0.67 [0.30 1.48]       | 0.323     |
| Both                               | 1.4 [0.74 2.75]      | 0.091                  | 6.24 [1.58 24.60]      | 0.009     |
| Tumor height                       |                      |                        |                        |           |
|                                    |                      |                        |                        |           |
|                                    |                      |                        |                        |           |
|                                    | 0.021                | 0.011                  |                        |           |
| < 5 cm                             | 1                    |                        | 1                      |           |
| 6 to 10 cm                         | 0.94 [0.22 4.11]     | 0.930                  | 0.47 [0.09 2.58]       | 0.385     |
| > 10 cm                            | 1.34 [0.30 6.02]     | 0.021                  | 0.21 [0.04 1.11]       | 0.065     |
| SBR grade                          |                      |                        |                        |           |
|                                    |                      |                        |                        |           |
|                                    | 0.066                | 0.241                  |                        |           |
| Grade I                            | 1.21 [0.57 2.56]     | 0.624                  | 2.24 [0.83 6.08]       | 0.112     |
| Grade II                           | 2.05 [0.92 4.57]     | 0.078                  | 2.48 [0.75 8.12]       | 0.135     |
| Tumor discovery                    |                      |                        |                        |           |
|                                    |                      |                        |                        |           |
|                                    | 0.037                | 0.711                  |                        |           |
| Screening                          | 1.64 [1.01 2.61]     | 0.037                  | 1.16 [0.53 2.51]       | 0.711     |
| Delay before treatment             |                      |                        |                        |           |
|                                    |                      |                        |                        |           |
|                                    | 0.015                | 0.011                  |                        |           |
| < 1 month                          | 1                    |                        | 1                      |           |
| 1 to 3 months                      | 0.50 [0.27 0.92]     | 0.026                  | 0.59 [0.24 1.47]       | 0.260     |
| 3 to 6 months                      | 0.86 [0.41 1.77]     | 0.677                  | 0.25 [0.067 0.95]      | 0.041     |
| 6 to 9 months                      | 0.40 [0.09 1.65]     | 0.204                  | 0.167 [0.02 1.39]      | 0.098     |
| 9 to 12 months                     | 0.00 [0.00 0.01]     | 0.962                  | 0.00 [0.00 0.01]       | 0.972     |
| > 12 months                        | 6.37 [3.74 7.13]     | 0.001                  | 5.12 [0.39 8.38]       | 0.0001    |

aHR = adjusted hazard ratio, CI = Confidence interval
Figure 1: survival curve at 5 years